ArticleOcular immunology and inflammation2026
Characteristics Associated with Appointment No-Show at an Academic Uveitis Service.
Article in Ocular immunology and inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo examine the association between patient characteristics and appointment no-show among uveitis patients.
methodsIn this retrospective cohort study from a tertiary, academic uveitis service, we examined appointment attendance outcomes for patients with a uveitis diagnosis code and at least one completed encounter. We examined demographic, clinical, and appointment status data from the electronic health record from 2019 to 2023. The main outcome was the presence of ≥ 1 appointment that was not attended and not cancelled within 24 h, defined as "no-show" (NS). Univariable and multivariable regression models with robust variance estimation were used to identify risk factors for NS. Risk ratios (RR) were calculated and reported with 95% confidence intervals (CI). Sensitivity analyses were conducted to account for count of total appointments, to assess NS rate over the time that excludes peak disruptions from coronavirus disease 2019, and to impute missing data.
results1,081 patients had 6843 scheduled encounters with the uveitis service, of whom 393 (36.4%) had at least one NS visit. In the adjusted analysis, younger age (adjusted RR [aRR] = 1.79, 95% CI: 1.03-3.13, age < 60 years compared to ≥ 80), Black race (aRR = 1.90, 95% CI: 1.58-2.27,
conclusionAge, race, insurance status, and blindness are associated with NS among uveitis patients. Targeted interventions may mitigate NS rates and consequent undertreatment of potentially blinding inflammatory eye diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.